Comparative Study
doi: 10.1016/j.bmcl.2009.01.033.
Epub 2009 Jan 15.
Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists
Affiliations
- PMID: 19196511
- DOI: 10.1016/j.bmcl.2009.01.033
Item in Clipboard
Comparative Study
Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists
Bioorg Med Chem Lett.
.
Abstract
A series of potent and orally bioavailable 3,4-diaminocyclobutenediones with various fluoroalkyl groups as alpha side chain were prepared and found to show significant improvements in the binding affinities towards both CXCR2 and CXCR1 receptors.
Similar articles
-
Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.Bioorg Med Chem Lett. 2009 Aug 1;19(15):4446-9. doi: 10.1016/j.bmcl.2009.05.049. Epub 2009 May 18. Bioorg Med Chem Lett. 2009. PMID: 19525110
-
Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.J Med Chem. 2006 Dec 28;49(26):7603-6. doi: 10.1021/jm0609622. J Med Chem. 2006. PMID: 17181143
-
C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.Bioorg Med Chem Lett. 2007 Jul 1;17(13):3778-83. doi: 10.1016/j.bmcl.2007.04.016. Epub 2007 Apr 10. Bioorg Med Chem Lett. 2007. PMID: 17459706
-
Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.Pulm Pharmacol Ther. 2015 Oct;34:37-45. doi: 10.1016/j.pupt.2015.08.002. Epub 2015 Aug 10. Pulm Pharmacol Ther. 2015. PMID: 26271598 Review.
-
ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.Pharmacol Ther. 2006 Oct;112(1):139-49. doi: 10.1016/j.pharmthera.2006.04.002. Epub 2006 May 23. Pharmacol Ther. 2006. PMID: 16720046 Review.
Cited by
-
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.Theranostics. 2017 Apr 7;7(6):1543-1588. doi: 10.7150/thno.15625. eCollection 2017. Theranostics. 2017. PMID: 28529637 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
